 |
> 1997 Publications
1. p53
tumor suppressor gene alterations in prostate cancer and potential
p53 gene therapy approaches.
Srivastava S, Moul JW:
Molecular Urol.1:151-158, 1997. |
2. Intracranial
metastatic adenocarcinoma of the prostate presenting as visual
disturbance.
Preston DM, Zeidman SM, Spevak M, Moul JW, Costabile RA:
Tech. In Urol., 3:51-53, 1997. |
3. PSA
thresholds for prostate cancer detection (letter).
Moul JW:
JAMA, 278:699, 1997. |
4. Molecular genetics of the testicular cancer.
Moul JW:
J Urol, 157:1552-1553, 1997. |
5. Increased risk of prostate cancer in African-American
men.
Moul JW:
Molecular Urol. 1:119-127, 1997. |
6.
Epidemiology and screening for prostate cancer.
Moul JW:
Am. J. Managed Care.3(8):1200-1205, 1997. |
7.
Editorial: Radical prostatectomy and cryotherapy - some
answers, more questions.
Moul JW
Journal of Urology, 157:256-257, 1997. |
8.
Prostate cancer-1997: Practicing what we preach.
Moul JW: Editorial:
J Urol, 158:1859-60, 1997. |
9.
What is proper cancer care in the era of managed care?
Moul JW:
Editorial to: Oncology, 11(1):72-78, 1997. |
10.
Prostate specific antigen in black and white men after
hormonal therapies for prostate cancer.
Moul JW:
Editorial comment to: J Urol, 158:154, 1997. |
11.
Prostate cancer and African-American men.
Moul JW:
Editorial comment to: Oncology, 11(5):611-618, 1997.
|
12.
Prospective evaluation of prostate specific antigen
and prostate specific antigen density in the detection of
carcinoma of the prostate: Ethnic variations.
Moul JW:
Editorial comment to: J Urol, 157:911-912, 1997. |
13.
Outcome of African American Men Screened for Prostate
Cancer: The Detroit Education and Early Detection Study.
Moul JW:
Editorial comment to: J Urol, 158: 149, 1997. |
14. A better definition of advanced prostate cancer
for today’s patients.
Moul JW:
Contemp Urol, pp.15-31. Dec. 1997. |
15. Age-specific reference ranges for serum prostate-specific
antigen in black men.
Morgan TO, Jacobsen SJ, McCarthy WF, Moul JW:
Urol. Digest, 3(1):1997. |
16.
Enzyme/producing gene therapy approach for breast cancer
using a recombinant adenovirus expressing E coli cytosine deaminase.
Li, Z, Shanmugam N, Katayose, D., Huber, B, Srivastava, S, Cowan,
K and Seth, P.
Cancer Gene Therapy 4:113-7,1997 |
17.
Suramin Keratosis: a Unique Skin Eruption in a Patient
Receiving Suramin for Metastatic Prostate Cancer.
Kenner JR, Sperling LC, Waselenko J, Dawson N, Sau P, Moul JW:
J Urol, 158:2245-46, 1997. |
18.
The influence of ejaculation on serum levels of prostate
specific antigen.
Heidenreich A, Vorreuther R, Neubauer S, Westphal J, Moul JW,
Englemann UH:
Journal of Urology, 157:209-211, 1997. |
19.
Synchronous bilateral testicular tumour: nonseminomatous
germ cell tumours and contralateral benign tumours.
Heidenreich A, Srivastava S, Engelman, UH:
Scan J Urol Nephrol (Sweden), 389-92, 1997. |
20.
Prognostic risk factors in low stage testicular germ
cell tumors.
Heidenreich A, Sesterhenn IA, Moul JW:
Cancer, 79:1641-1645, 1997. |
 Back
to Top |  Next
Page |
|
